NasdaqCM - Delayed Quote USD

Cyclerion Therapeutics, Inc. (CYCN)

3.0400 +0.2100 (+7.42%)
At close: April 25 at 4:00 PM EDT
Loading Chart for CYCN
DELL
  • Previous Close 2.8300
  • Open 2.7700
  • Bid --
  • Ask --
  • Day's Range 2.7700 - 3.0400
  • 52 Week Range 1.7500 - 6.7500
  • Volume 442
  • Avg. Volume 2,840
  • Market Cap (intraday) 8.239M
  • Beta (5Y Monthly) 1.83
  • PE Ratio (TTM) --
  • EPS (TTM) -5.9200
  • Earnings Date May 9, 2024 - May 13, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

www.cyclerion.com

1

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CYCN

Performance Overview: CYCN

Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CYCN
9.25%
S&P 500
5.84%

1-Year Return

CYCN
47.59%
S&P 500
22.03%

3-Year Return

CYCN
94.78%
S&P 500
20.77%

5-Year Return

CYCN
99.02%
S&P 500
72.46%

Compare To: CYCN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CYCN

Valuation Measures

Annual
As of 4/25/2024
  • Market Cap

    8.24M

  • Enterprise Value

    667.69k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.73

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    -0.07

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -38.34%

  • Return on Equity (ttm)

    -115.85%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -12.59M

  • Diluted EPS (ttm)

    -5.9200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.57M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -9.52M

Research Analysis: CYCN

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Company Insights: CYCN

Fair Value

3.0400 Current
 

Dividend Score

0 Low
CYCN
Sector Avg.
100 High
 

Hiring Score

0 Low
CYCN
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
CYCN
Sector Avg.
100 High
 

Research Reports: CYCN

  • Daily – Vickers Top Buyers & Sellers for 06/09/2021

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Daily – Vickers Top Buyers & Sellers for 05/11/2021

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Daily – Vickers Top Buyers & Sellers for 05/07/2021

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     

People Also Watch